HealthEquity, Inc. (HQY) stock analysis
Close on Nov 17, 2026Market cap $8.42BP/E 36.8Yield –
StockData Score
Prices as of Nov 16, 2026How the score works
Solid15 of 30 checks passed
HealthEquity passes 15 of the 30 checks behind our score; 6 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 3/6
- Growth
- 3/6
- Past performance
- 4/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
Trading below fair value
The share price of $104.58 is below our fair value estimate of $110.35.
Earnings grew over 5 years
Net income grew 89.4% a year on average over the last five fiscal years.
Revenue growing 10%+ a year
Revenue grew 15.1% a year over the last three fiscal years.
Interest well covered
Operating income covers interest expense 6.7 times.
What to watch
Margin of safety under 20%
The price is 5.2% below fair value, less than the 20% cushion we look for.
Return on equity under 15%
Return on equity was 11.4% over the last twelve months and averaged 2.7% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 9.8%, below the 10% that usually covers the cost of capital.
High debt
Debt is 46.8% of shareholders' equity, above the 40% we consider low.
Valuation3/6
P/E below its 5-year median
HealthEquity's P/E of 37.8 is below its own 5-year median of 76.6.
P/E above the industry
HealthEquity's P/E of 37.8 is above the Miscellaneous Business Services median of 25.6.
EV/EBITDA below its 5-year median
HealthEquity's EV/EBITDA of 18.3 is below its 5-year median of 28.6.
P/B above the industry
HealthEquity's price-to-book of 4.35 is above the Miscellaneous Business Services median of 2.53.
Trading below fair value
The share price of $104.58 is below our fair value estimate of $110.35.
Margin of safety under 20%
The price is 5.2% below fair value, less than the 20% cushion we look for.
Growth3/6
Revenue growing 10%+ a year
Revenue grew 15.1% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings growth not accelerating
Net income grew 62.2% over the last twelve months, against a 5-year average of 89.4% a year.
Growing slower than the industry
Revenue grew 7.3% over the last twelve months; the Miscellaneous Business Services median is 9.7%.
Guidance raised
HealthEquity raised its fiscal year ending January 31, 2027 revenues outlook on Aug 27, 2026.
Gross margin improving
Gross margin was 71.2% over the last twelve months, against 66.4% a year earlier.
Past performance4/6
Return on equity under 15%
Return on equity was 11.4% over the last twelve months and averaged 2.7% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 9.8%, below the 10% that usually covers the cost of capital.
Return on equity above the industry
HealthEquity's return on equity of 11.4% is above the Miscellaneous Business Services median of 6.3%.
Earnings grew over 5 years
Net income grew 89.4% a year on average over the last five fiscal years.
Net margin above its 5-year average
Net margin was 17.4% over the last twelve months, against a 5-year average of 4.2%.
Net margin above the industry
HealthEquity's net margin of 17.4% is above the Miscellaneous Business Services median of 4.6%.
Financial health5/6
High debt
Debt is 46.8% of shareholders' equity, above the 40% we consider low.
Debt falling against equity
Debt to equity fell from 71.6% five years ago to 46.8%.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 52.6% of total debt.
Interest well covered
Operating income covers interest expense 6.7 times.
Short-term assets cover short-term debts
Current assets are 2.99 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 5.00; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
HealthEquity has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$110.35
The share price is 5% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 45.0× | 76.6× | 25.6× | $124.65 | 40% |
| EV/EBITDA | 22.4× | 28.6× | 16.0× | $129.49 | 35% |
| P/B | 2.9× | 3.3× | 2.5× | $70.03 | 10% |
| Earnings power | 7.7% cost of equity | – | – | $54.47 | 15% |
| Fair value | $110.35 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 76.6
- Miscellaneous Business Services median 25.6
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $78.70M
- Value traded per 1% price move
- $59.15M
Downside
Medium risk
- Typical loss in a bad month
- 15.2%
- Volatility (annualized)
- 35%
- Sharpe ratio, 1 year
- 0.01
- Beta to the S&P 500 (5Y)
- 0.35
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +9.5% | +15.1% | +12.4% | +26.3% | |
| Gross profit | +17.5% | +22.9% | +17.1% | +28.8% | |
| Operating income | +98.6% | +229.0% | +56.8% | +28.6% | |
| Net income | +122.5% | – | +89.4% | +29.2% | |
| EPS, diluted | +125.7% | – | +83.0% | +24.3% | |
| Free cash flow | +34.7% | +45.7% | +22.0% | +34.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 11.3% | 0.7% | 10.2% | |
| Return on assets | 10.6% | 0.3% | 6.3% | |
| Current ratio | 12.79 | 2.25 | 3.27 | |
| Debt to equity | – | 0.72 | 0.45 | |
| Net debt to EBITDA | – | 4.39× | 1.34× | |
| Interest coverage | – | 1.0× | 5.6× | |
| Inventory turnover | 118.8× | – | – | |
| Capex to revenue | 2.0% | 1.8% | 0.1% | |
| Diluted shares | 60M | 76M | 87M |
Where the cash went
Fiscal 2022 to 2026, five years combined
HealthEquity generated $1.33B from operations and spent $438.77M on capital expenditure, dividends and share buybacks. 4% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 16.4% | 0.38× | 1.62× | 10.2% |
| FY2025 | 8.1% | 0.36× | 1.59× | 4.7% |
| FY2024 | 5.6% | 0.32× | 1.59× | 2.8% |
| FY2023 | -3.0% | 0.28× | 1.65× | -1.4% |
| FY2022 | -5.9% | 0.26× | 1.80× | -2.7% |
| FY2021 | 1.2% | 0.28× | 2.19× | 0.7% |
| FY2020 | 7.5% | 0.35× | 2.04× | 5.3% |
| FY2019 | 25.7% | 0.65× | 1.07× | 18.0% |
| FY2018 | 20.6% | 0.71× | 1.07× | 15.6% |
| FY2017 | 14.8% | 0.72× | 1.07× | 11.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
- ProfitableNet income above zero$215.20M
- Cash generatingOperating cash flow above zero$457.09M
- Return on assets improvedROA up on the prior year3.1% → 6.2%
- Earnings backed by cashOperating cash flow above net income$457.09M vs $215.20M
- Less leverageLong-term debt to assets fell30.6% → 28.3%
- Better liquidityCurrent ratio rose3.06 → 3.27
- No dilutionShare count did not rise89M → 87M
- Gross margin improvedGross margin up on the prior year64.78% → 69.52%
- More efficientAsset turnover rose0.38 → 0.38
See a number that looks wrong?